Advertisement

Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic

Published:November 29, 2022DOI:https://doi.org/10.1016/j.clgc.2022.11.020

      Highlights

      • We conducted this survey to understand how the COVID pandemic has impacted affected managment treatment of patients with mHSPC. Fifty medical oncologists across Canada responded to the questionnaire.
      • Not surprisingly, an increased uptake of ARATs and reduced use of docetaxel was observed.
      • How this trend will impact the uptake of triplet therapy (ADT+Docetaxel+ARAT), downstream treatment choices and overall outcomes remains to be seen.

      Abstract

      Background

      In metastatic hormone sensitive prostate cancer (mHSPC), treatment intensification with either docetaxel or an androgen-receptor-axis targeted therapy (ARAT), added to androgen deprivation therapy (ADT) is the new standard of care. To better understand patterns of treatment intensification in Canada and specifically how it has been influenced by the COVID-19 pandemic, we conducted a national survey of genitourinary medical oncologists from across Canada.

      Methods

      Using SurveyMonkey, we conducted an online survey of 119 medical oncologists in Canada from January 15 to January 27, 2021. The survey consisted of 16 questions, including demographics, and asked specifically about their approach to managing mHSPC before and during the pandemic.

      Results

      Overall there were 50/119 (42%) respondents. Most were male (65%), from Ontario (35%), practicing in academic centers (71%), with 45% reporting their practices focused primarily on genitourinary malignancies and one other tumor site. The majority were in practice 1 to 5 years (34%). Overall 65% indicated their practice patterns had changed since the pandemic, with 51% offering more ARATs and less docetaxel chemotherapy. In low volume mHSPC, the use of ARATs increased from 73% to 79%, while the use of docetaxel remained unaltered at 2%. In high volume disease, the use of ARATs increased from 63% to 84%, while the use of docetaxel decreased from 37% to 14%. Use of granulocyte colony stimulating factor (G-CSF) with docetaxel chemotherapy increased by 35%. Post-pandemic, 45% reported they intend to maintain these changes. Only 18% reported they had prostate cancer patients test positive for COVID-19, and all patients recovered.

      Conclusion

      Management of patients with mHSPC in Canada has changed during the pandemic, with increased uptake of ARATs and reduced use of docetaxel, a trend expected to continue beyond the pandemic. How this trend will impact uptake of triplet therapy (ADT + ARAT + Docetaxel), downstream treatment choices and overall outcomes remains to be seen.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Canadian Cancer Statistics Advisory Committee
        Canadian Cancer Statistics: A 2018 Special Report on cancer incidence by stage.
        Canadian Cancer Society, Toronto, ON2018 (Available at:) (accessed November 15, 2022)
        • Huggins C
        • Hodges CV.
        Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.
        J Urol. 2002; 168: 9-12https://doi.org/10.1016/s0022-5347(05)64820-3
        • Sweeney CJ
        • Chen YH
        • Carducci M
        • Liu G
        • Jarrard DF
        • Eisenberger M
        • et al.
        Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
        N Engl J Med. 2015; 373: 737-746https://doi.org/10.1056/NEJMoa1503747
        • Fizazi K
        • Tran N
        • Fein L
        • Matsubara N
        • Rodriguez-Antolin A
        • Alekseev BY
        • et al.
        Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
        Lancet Oncol. 2019; 20: 686-700https://doi.org/10.1016/S1470-2045(19)30082-8
        • Chi KN
        • Chowdhury S
        • Bjartell A
        • Chung BH
        • Pereira de Santana Gomes AJ
        Given R,et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study.
        J Clin Oncol. 2021; 39: 2294-2303https://doi.org/10.1200/JCO.20.03488
        • Davis ID
        • Martin AJ
        • Stockler MR
        • Begbie S
        Chi KN, Chowdhury S,et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer.
        N Engl J Med. 2019; 381: 121-131https://doi.org/10.1056/NEJMoa1903835
        • Fizazi K
        • Foulon S
        • Carles J
        • Roubaud G
        • McDermott R
        • Fléchon A
        • et al.
        Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
        Lancet. 2022; 399: 1695-1707https://doi.org/10.1016/S0140-6736(22)00367-1
        • Lalani AA
        • Chi KN
        • Heng DYC
        • Kollmannsberger CK
        • Sridhar SS
        Blais N,et al. Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic.
        Can Urol Assoc J. 2020; 14: E154-E158https://doi.org/10.5489/cuaj.6595
        • Tsaur I
        • Heidegger I
        • Bektic J
        • Kafka M
        • van den Bergh RCN
        • Hunting JCB
        • et al.
        A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
        Cancer Med. 2021; 10: 6354-6364https://doi.org/10.1002/cam4.4184
        • Smith TJ
        • Bohlke K
        • Lyman GH
        • Carson KR
        • Crawford J
        • Cross SJ
        • et al.
        Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update.
        J Clin Oncol. 2015; 33: 3199-3212https://doi.org/10.1200/JCO.2015.62.3488
        • Liu C
        • Zhao Y
        • Okwan-Duodu D
        • Basho R
        • Cui X.
        COVID-19 in cancer patients: risk, clinical features, and management.
        Cancer Biol Med. 2020; 17: 519-527https://doi.org/10.20892/j.issn.2095-3941.2020.0289
        • Heath EI
        • Dyson GE
        • Cackowski FC
        • Hafron J
        • Powell I.
        Treatment intensification patterns and utilization in patients with metastatic castration-sensitive prostate cancer.
        Clin Genitourin Cancer. 2022; 20: 524-532https://doi.org/10.1016/j.clgc.2022.06.017
        • Ryan CJ
        • Ke X
        • Lafeuille MH
        • Romdhani H
        • Kinkead F
        • Lefebvre P
        • et al.
        Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States.
        J Urol. 2021; 206: 1420-1429https://doi.org/10.1097/JU.0000000000002121
        • Ke X
        • Lafeuille M-H
        • Romdhani H
        • Kinkead F
        • Francis PSJ
        • D'Andrea D
        • et al.
        Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US).
        J Clin Oncol. 2020; 38 (e19131 -e)
        • Fillmore NR
        • La J
        • Szalat RE
        • Tuck DP
        • Nguyen V
        • Yildirim C
        • et al.
        Prevalence and outcome of COVID-19 infection in cancer patients: a national veterans affairs study.
        J Natl Cancer Inst. 2021; 113: 691-698https://doi.org/10.1093/jnci/djaa159
        • Gianfrancesco M
        • Hyrich KL
        • Al-Adely S
        • Carmona L
        • Danila MI
        • Gossec L
        • et al.
        Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
        Ann Rheum Dis. 2020; 79: 859-866https://doi.org/10.1136/annrheumdis-2020-217871
        • Brtnikova M
        • Crane LA
        • Allison MA
        • Hurley LP
        • Beaty BL
        • Kempe A.
        A method for achieving high response rates in national surveys of U.S. primary care physicians.
        PLoS One. 2018; 13 (Published 2018 Aug 23)e0202755https://doi.org/10.1371/journal.pone.0202755